company background image

Healthia ASX:HLA Stock Report

Last Price


Market Cap







08 Aug, 2022


Company Financials +
HLA fundamental analysis
Snowflake Score
Future Growth4/6
Past Performance1/6
Financial Health2/6

HLA Stock Overview

Healthia Limited provides health services in Australia.

Healthia Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Healthia
Historical stock prices
Current Share PriceAU$1.64
52 Week HighAU$2.44
52 Week LowAU$1.26
1 Month Change10.07%
3 Month Change-2.96%
1 Year Change-17.59%
3 Year Change64.00%
5 Year Changen/a
Change since IPO37.24%

Recent News & Updates

Shareholder Returns

HLAAU HealthcareAU Market

Return vs Industry: HLA underperformed the Australian Healthcare industry which returned -4% over the past year.

Return vs Market: HLA underperformed the Australian Market which returned -7.9% over the past year.

Price Volatility

Is HLA's price volatile compared to industry and market?
HLA volatility
HLA Average Weekly Movement6.4%
Healthcare Industry Average Movement5.6%
Market Average Movement10.5%
10% most volatile stocks in AU Market17.6%
10% least volatile stocks in AU Market4.6%

Stable Share Price: HLA is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: HLA's weekly volatility (6%) has been stable over the past year.

About the Company

2018n/aWes Coote

Healthia Limited provides health services in Australia. The company operates 94 podiatry clinics under the My FootDr brand; 52 physiotherapy clinics; and 14 hand therapy clinics, as well as manufactures and sells 3D printed orthotic devices for podiatry clinics. It also offers podiatry and foot and nail care products, hand and upper limb therapies, orthopaedic, optometry, pilates, retail footwear, custom orthotic manufacturing services, and medical products to podiatrists, hospitals, medical centres, nursing homes, and allied health professionals.

Healthia Fundamentals Summary

How do Healthia's earnings and revenue compare to its market cap?
HLA fundamental statistics
Market CapAU$210.44m
Earnings (TTM)AU$161.00k
Revenue (TTM)AU$167.82m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HLA income statement (TTM)
Cost of RevenueAU$119.09m
Gross ProfitAU$48.73m
Other ExpensesAU$48.57m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 31, 2022

Earnings per share (EPS)0.0013
Gross Margin29.04%
Net Profit Margin0.095%
Debt/Equity Ratio40.4%

How did HLA perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is HLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLA?

Other financial metrics that can be useful for relative valuation.

HLA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.2x
Enterprise Value/EBITDA25.7x
PEG Ratio40.8x

Price to Sales Ratio vs Peers

How does HLA's PS Ratio compare to its peers?

HLA PS Ratio vs Peers
The above table shows the PS ratio for HLA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average13.4x
CAJ Capitol Health
AHX Apiam Animal Health
SLA SILK Laser Australia
HLA Healthia

Price-To-Sales vs Peers: HLA is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (13.4x).

Price to Earnings Ratio vs Industry

How does HLA's PE Ratio compare vs other companies in the AU Healthcare Industry?

Price-To-Sales vs Industry: HLA is good value based on its Price-To-Sales Ratio (1.3x) compared to the Australian Healthcare industry average (1.4x)

Price to Sales Ratio vs Fair Ratio

What is HLA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: HLA is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Share Price vs Fair Value

What is the Fair Price of HLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HLA (A$1.64) is trading below our estimate of fair value (A$4.46)

Significantly Below Fair Value: HLA is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Healthia forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score


Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HLA's forecast earnings growth (32.2% per year) is above the savings rate (1.8%).

Earnings vs Market: HLA's earnings (32.2% per year) are forecast to grow faster than the Australian market (6.1% per year).

High Growth Earnings: HLA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HLA's revenue (10.1% per year) is forecast to grow faster than the Australian market (5.7% per year).

High Growth Revenue: HLA's revenue (10.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HLA's Return on Equity is forecast to be low in 3 years time (12.3%).

Discover growth companies

Past Performance

How has Healthia performed over the past 5 years?

Past Performance Score


Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: HLA has a large one-off loss of A$4.5M impacting its December 31 2021 financial results.

Growing Profit Margin: HLA's current net profit margins (0.1%) are lower than last year (6.6%).

Past Earnings Growth Analysis

Earnings Trend: HLA's earnings have grown significantly by 44.5% per year over the past 5 years.

Accelerating Growth: HLA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: HLA had negative earnings growth (-97.7%) over the past year, making it difficult to compare to the Healthcare industry average (29.8%).

Return on Equity

High ROE: HLA's Return on Equity (1.9%) is considered low.

Discover strong past performing companies

Financial Health

How is Healthia's financial position?

Financial Health Score


Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: HLA's short term assets (A$26.7M) do not cover its short term liabilities (A$46.5M).

Long Term Liabilities: HLA's short term assets (A$26.7M) do not cover its long term liabilities (A$125.7M).

Debt to Equity History and Analysis

Debt Level: HLA's net debt to equity ratio (36.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if HLA's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: HLA's debt is well covered by operating cash flow (22%).

Interest Coverage: HLA's interest payments on its debt are not well covered by EBIT (3x coverage).

Balance Sheet

Discover healthy companies


What is Healthia current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: HLA's dividend (2.74%) is higher than the bottom 25% of dividend payers in the Australian market (2.62%).

High Dividend: HLA's dividend (2.74%) is low compared to the top 25% of dividend payers in the Australian market (6.24%).

Stability and Growth of Payments

Stable Dividend: HLA has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: HLA's dividend payments have increased, but the company has only paid a dividend for 2 years.

Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (2772.6%), HLA's dividend payments are not well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (48.2%), HLA's dividend payments are well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Wes Coote





Mr. Wesley James Coote, also known as Wes, B.Com., C.A., ACIS, serves as the Managing Director of Evolve Salons Limited. Mr. Coote has been Group Managing Director, Chief Executive Officer and Director at...

CEO Compensation Analysis

Compensation vs Market: Wes's total compensation ($USD276.03K) is about average for companies of similar size in the Australian market ($USD279.73K).

Compensation vs Earnings: Wes's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

Leadership Team

Experienced Management: HLA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Experienced Board: HLA's board of directors are considered experienced (4.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.2%.

Top Shareholders

Company Information

Healthia Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Healthia Limited
  • Ticker: HLA
  • Exchange: ASX
  • Founded: 2018
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: AU$210.439m
  • Shares outstanding: 128.32m
  • Website:


  • Healthia Limited
  • East Tower
  • Level 4
  • Bowen Hills
  • Queensland
  • 4006
  • Australia


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/08 00:00
End of Day Share Price2022/08/08 00:00
Annual Earnings2021/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.